Douglas Salm, MD
Ophthalmology · Appleton, WINPI 1033373600
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Amgen accounts for 67.6% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2023 at $17,462 and has fallen 72.7% since, to $4,764 in 2025. Among ophthalmology clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 327 payments — averaging $117.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$26K
- Alcon$3K
- Carl Zeiss Meditec USA, Inc.$3K
- AbbVie$2K
- Glaukos Corporation$499
- Astellas Pharma US Inc$285
- plus $3K from 25 others
What the payments were for
- Consulting fees$4,05011%
- Speaking & faculty fees$16,88944%
- Travel & lodging$6,54917%
- Food & beverage$7,42819%
- Education$1440%
- Gifts$450%
- Other$3,1988%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 68 | $25,895 |
| Alcon | 54 | $3,455 |
| Carl Zeiss Meditec USA, Inc. | 1 | $3,198 |
| AbbVie(2 entities) | 54 | $2,424 |
| Glaukos Corporation | 13 | $499 |
| Astellas Pharma US Inc | 10 | $285 |
| Mallinckrodt Hospital Products Inc. | 9 | $282 |
| Regeneron Healthcare Solutions, Inc. | 14 | $274 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 15 | $245 |
| Bausch & Lomb Americas Inc. | 13 | $238 |
| Ocular Therapeutix, Inc. | 11 | $182 |
| Novartis | 11 | $181 |
| Rayner Intraocular Lenses Limited | 7 | $164 |
| Kala Pharmaceuticals, Inc. | 8 | $132 |
| The Cameron-ehlen Group, Inc. | 2 | $124 |
| Apellis Pharmaceuticals, Inc. | 7 | $120 |
| Omeros Corporation | 5 | $100 |
| Harrow Eye, LLC | 5 | $99 |
| Sun Pharmaceutical Industries Inc. | 3 | $82 |
| Oyster Point Pharma, Inc. | 3 | $58 |
| Dompe US, Inc. | 2 | $46 |
| Rxsight Inc | 1 | $39 |
| Thea Pharma Inc. | 2 | $38 |
| Genentech USA, Inc. | 2 | $25 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $23 |
| Biogen | 1 | $20 |
| Tarsus Pharmaceuticals, Inc. | 1 | $18 |
| NEW World Medical,inc. | 1 | $17 |
| Aerie Pharmaceuticals, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $13 |
| LKC Technologies, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$24,777
- LUMERA 700$3,198
- LenSx$2,525
- XEN$1,196
- XEN GLAUCOMA TREATMENT SYSTEM$333
- iDoseTR$191
- DURYSTA$106
How this compares
$38,303 in reported general payments places this provider in the 95th percentile of 337 ophthalmology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 51 | $28,757 |
| RestasisCyclosporine | 13 | $19,716 |
| Prednisolone Acetate | 403 | $17,222 |
| RocklatanNetarsudil Mesylat/Latanoprost | 20 | $15,541 |
| CombiganBrimonidine Tartrate/Timolol | 50 | $14,604 |
| ProlensaBromfenac Sodium | 28 | $9,836 |
| Latanoprost | 694 | $9,514 |
| RhopressaNetarsudil Mesylate | 25 | $9,297 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 25 | $6,821 |
| Alphagan PBrimonidine Tartrate | 21 | $6,542 |
| Bimatoprost | 33 | $6,080 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 21 | $5,347 |
| Timolol Maleate | 237 | $5,228 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 232 | $4,802 |
| Bromfenac Sodium | 19 | $3,619 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $2,424 | $69,619135 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $17 | $24,83845 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $245 | $12,41144 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 337 ophthalmology providers in Wisconsin.
Other ophthalmology in Appleton
- Michael VrabecAppleton$20K
- Avery AlexanderAppleton$9K
- Inder SinghRacine$2.5M
- Deepak SambharaWausau$388K
- John VukichWauwatosa$356K
- Eugene EldridgeKenosha$294K
- Michael ShapiroMadison$71K
- Julia AgapovMadison$26K
- Thomas HarveyChippewa Falls$23K
- Philip SmithMinocqua$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.